公开(公告)号：US20170248598A1

公开(公告)日：2017-08-31

申请号：US15587907

申请日：2017-05-05

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Dieter Roessler ,  Barbara Upmeier ,  Toralf Zarnt

IPC: G01N33/569 ,  C07K14/44 ,  G01N33/564

CPC classification number: G01N33/56905 ,  C07K14/44 ,  C07K2319/21 ,  C07K2319/40 ,  C07K2319/70 ,  G01N33/564 ,  G01N2333/44 ,  G01N2469/20 ,  G01N2800/26

Abstract: The invention concerns variants of JL7 antigens that are suitable for detecting antibodies against Trypanosoma cruzi (causing Chagas disease) in an isolated biological sample. These antigens comprise a JL7 specific amino acid sequence, said JL7 specific sequence consisting of two copies of SEQ ID NO. 2, wherein each of said two copies has an amino acid identity of at least 90% to SEQ ID NO.2 and wherein no further Trypanosoma cruzi specific amino acid sequences are present in said polypeptide. The invention also concerns a composition of polypeptides useful for the detection of antibodies against Trypanosoma cruzi that comprises the above characterized JL7 antigen along with at least one of T. cruzi polypeptides 1F8, Cruzipain, KMP-11 and PAR-2. Moreover, it relates to a method for producing JL7 antigen as well as to diagnostic methods for detecting T. cruzi antibodies using the JL7 polypeptide. In addition, the invention concerns a reagent kit comprising said JL7 polypeptides or composition of Trypanosoma cruzi polypeptides.

公开(公告)号：US09081016B2

公开(公告)日：2015-07-14

申请号：US13766130

申请日：2013-02-13

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Veit Peter Grunert ,  Ursula Klause ,  Pavel Kubalec ,  Matthias Rothfuss ,  Barbara Upmeier

IPC: C40B30/04 ,  G01N33/68

CPC classification number: G01N33/6854 ,  C40B30/04 ,  G01N2800/52

Abstract: Methods and system for determination of an anti- antibody (anti- AB) in vitro in a sample from a patient treated with a therapeutic monoclonal antibody (TmAB). Also, methods and systems for the determination of antigen specific antibodies of a particular immunoglobulin class and for the identification of a patient who is at risk of developing an adverse drug reaction (ADR) during treatment with a TmAB.

Abstract translation: 在用治疗性单克隆抗体（TmAB）治疗的患者的样品中体外测定抗<治疗性单克隆抗体>抗体（抗-TABAB> AB）的方法和系统。 而且，用于确定特定免疫球蛋白类别的抗原特异性抗体的方法和系统以及用于在用TmAB治疗期间鉴定患有不良药物反应（ADR）的风险的患者的方法和系统。